Customizing poly(lactic-co-glycolic acid) particles for biomedical applications

Swider, Edyta; Koshkina, Olga; Tel, Jurjen; Cruz, Luis J.; Vries, I. Jolanda M. de; Srinivas, Mangala

doi:10.1016/j.actbio.2018.04.006

Cited by 264 publications

(204 citation statements)

References 124 publications

Supporting

Mentioning

202

Contrasting

Unclassified

Order By: Relevance

“…While many of these delivery systems have been reviewed elsewhere [80], efforts have focused on developing NPs from poly(lactic-co-glycolic acid) (PLGA), a biocompatible and biodegradable polymer, well-known to the FDA [81]. In addition to their favorable safety profiles [82,83], drug release from PLGA NPs is highly tunable by adjusting polymer molecular weight and ratio of lactic to glycolic acid [84]. Recently, Mandl et al showed that NP size can be tuned to alter biodistribution and accumulation of NPs in sites of interest, such bone marrow or lung [85].…”

Section: Plga Nanoparticle-mediated Delivery Of Pnasmentioning

confidence: 99%

Peptide Nucleic Acids and Gene Editing: Perspectives on Structure and Repair

et al. 2020

View full text Add to dashboard Cite

Unusual nucleic acid structures are salient triggers of endogenous repair and can occur in sequence-specific contexts. Peptide nucleic acids (PNAs) rely on these principles to achieve non-enzymatic gene editing. By forming high-affinity heterotriplex structures within the genome, PNAs have been used to correct multiple human disease-relevant mutations with low off-target effects. Advances in molecular design, chemical modification, and delivery have enabled systemic in vivo application of PNAs resulting in detectable editing in preclinical mouse models. In a model of β-thalassemia, treated animals demonstrated clinically relevant protein restoration and disease phenotype amelioration, suggesting a potential for curative therapeutic application of PNAs to monogenic disorders. This review discusses the rationale and advances of PNA technologies and their application to gene editing with an emphasis on structural biochemistry and repair.

show abstract

Section: Plga Nanoparticle-mediated Delivery Of Pnasmentioning

confidence: 99%

Peptide Nucleic Acids and Gene Editing: Perspectives on Structure and Repair

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Poly(lactide‐coglycolic acid) (PLGA) nanoparticle (NP) has been widely used in the field of nanomedicine due to its excellent biocompatibility and biodegradability. [ 1 ] It also favors the clinical translation since PLGA was approved by the US Food and Drug Administration (FDA). [ 2 ] Recently, the chemotherapeutic drug and photosensitizer coloaded PLGA NPs have emerged as a promising combined chemo‐photothermal therapy in the malignant cancer due to their synergistic antitumor effect and reduced tumor recurrence.…”

Section: Introductionmentioning

confidence: 99%

Dissolving Microneedles Loading TPGS Biphasic Functionalized PLGA Nanoparticles for Efficient Chemo‐Photothermal Combined Therapy of Melanoma

Peng

Huang

Feng

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

The poly (lactic‐co‐glycolic acid) nanoparticle (PLGA NP) has been widely used in the biomedical field. However, it is insensitive to degradation upon laser irradiation, resulting in a limited increase in drug release, which compromises the therapeutic efficacy. To actively promote drug release, the biphasic α‐tocopheryl succinate (TPGS) functionalized PLGA NPs (PTNPs) are developed by introducing TPGS into the aqueous and organic phase to generate pores in the PLGA core during preparation. Paclitaxel and indocyanine green are encapsulated in the PTNPs to realize chemo‐photothermal combined therapy, and PTNPs are delivered through dissolving microneedles (DMNs) for local treatment in melanoma. PTNPs show enhanced drug release and improved cytotoxicity due to their greater ability in inhibiting cell microtubule depolymerization. In vivo tumor suppression investigation and ki‐67 immunohistochemical staining of tumor tissue further show the superiority of PTNPs loaded DMNs against tumor growth, and photothermal therapy synergistically enhances the chemotherapeutic effect of PTNPs. Moreover, the living imaging of mice demonstrates that the drug is successfully retained in the tumor tissue to avoid it entering into the circulation and producing adverse effects. Therefore, the PTNPs loaded DMNs show a favorable prospect in the treatment of superficial tumor.

show abstract

“…Nanoparticles serve as a suitable platform to develop such localized interventions since they have been used to package and deliver diverse therapeutic agents. In particular, the polymer poly (lactic-co-glycolic acid) (PLGA), which has excellent biocompatibility and biodegradability, has been U.S. Food and Drug Administration (FDA) approved and extensively used to deliver synergistic drug combinations [2][3][4][5]. These properties make PLGA an excellent candidate for applications involving the controlled release of encapsulated agents and improved drug pharmacokinetics in vivo [6,7].…”

Section: Introductionmentioning

confidence: 99%

Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma

et al. 2020

View full text Add to dashboard Cite

In this study, we describe poly (lactic-co-glycolic) acid (PLGA)-based nanoparticles that combine photothermal therapy (PTT) with epigenetic therapy for melanoma. Specifically, we co-encapsulated indocyanine green (ICG), a PTT agent, and Nexturastat A (NextA), an epigenetic drug within PLGA nanoparticles (ICG-NextA-PLGA; INAPs). We hypothesized that combining PTT with epigenetic therapy elicits favorable cytotoxic and immunomodulatory responses that result in improved survival in melanoma-bearing mice. We utilized a nanoemulsion synthesis scheme to co-encapsulate ICG and NextA within stable and monodispersed INAPs. The INAPs exhibited concentration-dependent and near-infrared (NIR) laser power-dependent photothermal heating characteristics, and functioned as effective single-use agents for PTT of melanoma cells in vitro. The INAPs functioned as effective epigenetic therapy agents by inhibiting the expression of pan-histone deacetylase (HDAC) and HDAC6-specific activity in melanoma cells in vitro. When used for both PTT and epigenetic therapy in vitro, the INAPs increased the expression of co-stimulatory molecules and major histocompatibility complex (MHC) Class I in melanoma cells relative to controls. These advantages persisted in vivo in a syngeneic murine model of melanoma, where the combination therapy slowed tumor progression and improved median survival. These findings demonstrate the potential of INAPs as agents of PTT and epigenetic therapy for melanoma.

show abstract

Customizing poly(lactic-co-glycolic acid) particles for biomedical applications

Cited by 264 publications

References 124 publications

Peptide Nucleic Acids and Gene Editing: Perspectives on Structure and Repair

Peptide Nucleic Acids and Gene Editing: Perspectives on Structure and Repair

Dissolving Microneedles Loading TPGS Biphasic Functionalized PLGA Nanoparticles for Efficient Chemo‐Photothermal Combined Therapy of Melanoma

Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma

Contact Info

Product

Resources

About